Alnylam Pharmace. Stock
Price
Target price
€259.80
€259.80
-4.500%
-12.2
-4.500%
€422.41
22:26 / Tradegate
WKN: A0CBCK / Symbol: ALNY / Name: Alnylam Pharms / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Alnylam Pharmace. Stock
Alnylam Pharmace. took a tumble today and lost -€12.200 (-4.500%).
The stock is an absolute favorite of our community with 55 Buy predictions and no Sell predictions.
As a result the target price of 422 € shows a very positive potential of 62.43% compared to the current price of 259.8 € for Alnylam Pharmace..
For the coming years our community has positive and negative things to say abot the Alnylam Pharmace. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "EBIT growth" there were negative voices in the community.
Alnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Pros and Cons of Alnylam Pharmace. in the next few years
Pros
?
S********** s********
?
C******** o* t** e**********
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Alnylam Pharmace. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Alnylam Pharmace. | -4.500% | -9.024% | -20.794% | 4.428% | -19.953% | 35.026% | 98.740% |
| Iovance Biotherapeutics Inc. | -3.200% | 5.962% | 4.021% | -57.137% | -7.841% | -68.401% | -94.546% |
| United Therapeutics | -0.270% | -2.005% | -4.843% | 17.571% | -6.202% | 67.699% | 184.255% |
| Neurocrine Bioscience | -10.750% | -0.856% | -0.771% | 2.705% | -5.121% | 19.863% | 21.664% |
Comments
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by analysts at Needham & Company LLC from $529.00 to $510.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its "buy" rating reaffirmed by analysts at Bank of America Corporation.
Show more
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by analysts at HC Wainwright from $570.00 to $510.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ALNY provided by MarketBeat
